Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib with Chemo and Olaparib in High-Risk Ovarian Cancer
NCT06437353Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in ovarian cancer, sponsored by Anhui Provincial Tumor Hospital. Started May 2024; status: recruiting.
02
Drugs
surufatinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06437353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437353.